Five Most Prescribed Antimalarial Drugs and Geographic Activity
The five most prescribed antimalarial drugs are chloroquine, artemisinin-based combination therapies (ACTs), mefloquine, sulfadoxine-pyrimethamine, and quinine, with their geographic effectiveness varying dramatically based on regional resistance patterns.
The Five Core Antimalarials
1. Chloroquine
- Active geographic regions: North Africa, Middle East (excluding parts of Oman, Yemen, Iran), Central America (limited areas), and parts of the Caribbean
- Resistance-limited regions: Southeast Asia (nearly 100% resistance), Amazon region (nearly 100% resistance), and sub-Saharan Africa (variable but widespread resistance) 1, 2
- Remains effective for P. vivax in most locations except Papua New Guinea, Irian Jaya, and Pacific islands 2
- Still recommended for low-risk areas like Turkish tourist areas and most of North Africa 3
2. Artemisinin-Based Combination Therapies (ACTs)
- Active geographic regions: Currently effective worldwide, though emerging resistance detected
- Resistance concerns: Greater Mekong subregion in Southeast Asia showing artemisinin resistance 4
- Became first-line treatment globally since mid-2000s 4
- Artesunate demonstrates the fastest parasite clearance times across all antimalarials 5
- Critical caveat: The Greater Mekong region is the alarming source from which chloroquine and pyrimethamine/sulfadoxine resistance previously spread to Africa, making artemisinin resistance containment urgent 4
3. Mefloquine
- Active geographic regions: Sub-Saharan Africa (as first-line for chloroquine-resistant areas), parts of Southeast Asia (outside Thailand)
- Resistance-limited regions: Thailand and border areas with significant resistance 2
- Recommended for high-risk areas when chloroquine cannot be used 3
- Can be used in second and third trimesters of pregnancy 3
- Important limitation: Significant neuropsychiatric side effects; unsuitable for children and during lactation 3
4. Sulfadoxine-Pyrimethamine (SP)
- Active geographic regions: Tropical Africa (still useful)
- Resistance-limited regions: Southeast Asia (ineffective), Amazon region (ineffective), Thailand (42% high-grade resistance) 5, 2
- High pooled prevalence of resistance markers (pfdhfr 85.7%, pfdhps 73.7%) globally 6
- Critical warning: No longer recommended for chemoprophylaxis due to agranulocytosis risk 3
- Persistent use pressure continues driving resistance, particularly in Africa 6
5. Quinine
- Active geographic regions: Remains effective worldwide, particularly for severe/complicated malaria
- Partial resistance: Thailand shows decreased sensitivity, but remains effective when combined with tetracycline or doxycycline 2
- Preferred therapy for severe or complicated malaria via intravenous route 2
- Practical limitation: Poor compliance due to increasing side effects with 7-day courses 3
Geographic Resistance Patterns: Critical Decision Points
Southeast Asia (Greater Mekong): This region is the epicenter of antimalarial resistance emergence. Chloroquine and SP are essentially ineffective. Mefloquine resistance is problematic in Thailand. Artemisinin resistance is now confirmed here 4, 2. Use ACTs with caution and monitor treatment response closely.
Sub-Saharan Africa: Chloroquine resistance is widespread but not universal. SP remains useful. ACTs are first-line. Mefloquine is effective for chloroquine-resistant strains 3, 2. The pfk13 marker prevalence of 45.0% signals emerging artemisinin resistance 6.
Amazon Region: Nearly 100% chloroquine resistance. SP is ineffective. ACTs and mefloquine are primary options 2.
North Africa/Middle East: Low malaria risk in tourist areas. Chloroquine remains effective in most regions except parts of Oman, Yemen, Iran, and Afghanistan where chloroquine-resistant falciparum occurs 3.
Special Populations
Pregnancy: Chloroquine and proguanil have long safety records. Mefloquine can be used in second and third trimesters. Pregnant women should avoid endemic areas when possible due to severe malaria risk 3.
Renal failure: Mefloquine or doxycycline preferred as they are hepatically metabolized. Proguanil requires dose adjustment based on creatinine clearance 3.
Asplenic patients: At particular risk for severe malaria; require meticulous antimosquito measures and strict chemoprophylaxis compliance 3.